Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial

Bingfeng Han,Wu Liu,Juan Du,Hanyu Liu,Tianshuo Zhao,Shubo Yang,Shuai Wang,Sihui Zhang,Bei Liu,Yaqiong Liu,Fuqiang Cui
DOI: https://doi.org/10.1016/j.vaccine.2021.04.058
IF: 4.169
2021-06-01
Vaccine
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>Hepatitis B virus (HBV) infection remains a global public health challenge. Patients with diabetes are at greater risk of HBV infection than healthy people. The immunogenicity and safety of two major hepatitis B vaccines were evaluated in Chinese patients with diabetes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>In this phase IV, open-label, randomized, controlled study, participants with diabetes were randomly recruited from 6 township health centers in Gansu Province and received either a 3-dose Saccharomyces cerevisiae recombinant hepatitis B vaccine (Group D20SC 0-1-6, n = 113) or a 3-dose Chinese hamster ovary cell (CHO) recombinant hepatitis B vaccine (Group D20CHO 0-1-6, n = 119). Healthy control groups were randomly recruited from the same 6 health centers and received 3 doses of the saccharomyces cerevisiae recombinant hepatitis B vaccine (Group ND20SC 0-1-6, n = 77). Immunogenicity, including seroconversion rate and geometric mean concentration (GMC) at 1 month after three doses of vaccination, and safety were assessed. The seroconversion rate was defined as the concentration of HBsAb ≥ 10 mIU/mL.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The seroconversion rates of Group D20SC 0-1-6, Group D20CHO 0-1-6 and Group ND20SC 0-1-6 were 89.6%, 91.4% and 97.1%, respectively, in the per-protocol analysis, and these differences were not statistically significant. The antibody concentration in Group D20SC 0-1-6 (GMC = 601 mIU/mL) was lower than that of the healthy control group (GMC = 1465 mIU/mL), but no significant difference was found in the GMC between the Group D20CHO 0-1-6 (GMC = 778 mIU/mL) and Group D20SC 0-1-6. Adverse events (AEs) were comparable between groups, and no serious AEs were found in these three groups.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>The Saccharomyces cerevisiae recombinant and CHO recombinant hepatitis B vaccines in China can induce good immunogenicity in a diabetic population, although the antibody concentration may be lower, indicating the feasibility of vaccinating a large number of diabetic patients in China with these vaccines.</p>
immunology,medicine, research & experimental
What problem does this paper attempt to address?
This paper aims to address the immunogenicity and safety issues of hepatitis B vaccination in Chinese patients with type 2 diabetes. Specifically, the study evaluated the immune responses and safety of two major hepatitis B vaccines (yeast - recombinant hepatitis B vaccine and CHO - cell - recombinant hepatitis B vaccine) in Chinese patients with type 2 diabetes. ### Research Background - **Hepatitis B virus (HBV) infection**: A global public health challenge. According to the World Health Organization (WHO), in 2015, 257 million people had chronic hepatitis B infection, and approximately 887,000 people died from hepatitis B - related diseases. - **Risks for diabetic patients**: Diabetic patients are more likely to be infected with HBV than healthy people. The Emerging Infections Program (EIP) in the United States reported that the risk of acute HBV infection in diabetic patients is almost twice that of healthy adults. A meta - analysis showed that the risk of HBV infection in diabetic patients is 1.55 times higher than that in non - diabetic patients. - **Vaccination recommendations**: In 2017, the WHO recommended hepatitis B vaccination for diabetic patients for the first time. In 2019, the Chinese guidelines for the prevention and treatment of chronic hepatitis B first pointed out that the diabetic population is a high - risk group for HBV infection and recommended hepatitis B vaccination. ### Research Objectives - **Evaluating immunogenicity**: Comparing the seroconversion rates and geometric mean concentrations (GMC) of antibodies of the two vaccines in diabetic patients. - **Evaluating safety**: Recording and comparing adverse events (AEs) between different groups. ### Methods - **Study design**: This is a phase IV, open - label, randomized controlled trial. - **Participants**: Diabetic patients and healthy control groups were randomly recruited from six township health centers in Jingtai County, Gansu Province. - **Vaccines**: Diabetic patients were divided into two groups and vaccinated with yeast - recombinant hepatitis B vaccine (D20SC 0 - 1 - 6 group) and CHO - cell - recombinant hepatitis B vaccine (D20CHO 0 - 1 - 6 group), respectively. The healthy control group was vaccinated with yeast - recombinant hepatitis B vaccine (ND20SC 0 - 1 - 6 group). - **Evaluation indicators**: Seroconversion rate (HBsAb concentration ≥ 10 mIU/mL) and geometric mean concentration of antibodies (GMC). ### Results - **Seroconversion rate**: The seroconversion rates of the D20SC 0 - 1 - 6 group, D20CHO 0 - 1 - 6 group, and ND20SC 0 - 1 - 6 group were 89.6%, 91.4%, and 97.1%, respectively, with no statistically significant differences. - **Antibody concentration**: The GMC of the D20SC 0 - 1 - 6 group was 601 mIU/mL, the GMC of the D20CHO 0 - 1 - 6 group was 778 mIU/mL, and the GMC of the healthy control group was 1465 mIU/mL. The antibody concentration in the D20SC 0 - 1 - 6 group was significantly lower than that in the healthy control group, but there was no significant difference between the D20CHO 0 - 1 - 6 group and the D20SC 0 - 1 - 6 group. - **Safety**: The incidence of adverse events was comparable among the groups, and no serious adverse events were found. ### Conclusions - **Immunogenicity**: Yeast - recombinant and CHO - cell - recombinant hepatitis B vaccines have good immunogenicity in Chinese diabetic patients, although the antibody concentrations may be lower. - **Safety**: The two vaccines are safe for use in diabetic patients and can be widely used to prevent HBV infection. ### Discussion - **Immune response**: The antibody concentrations in diabetic patients are lower than those in healthy individuals, which may be related to certain human leukocyte antigen (HLA) alleles. - **Long - term protection**: Future studies will further explore the immune persistence and rare adverse events after vaccination in diabetic patients. ### Future Research Directions - **Immune persistence**: Continue to study the immune persistence after vaccination in diabetic patients to provide a basis for antibody monitoring frequency. - **Non - responders**: Pay further attention to non - responders to understand their characteristics and reasons. ### Statements - **Conflict of interest**: The authors declare that there are no known financial interests or personal relationships that may affect the work of this paper. - **Acknowledgements**: Thanks to the technical guidance of the Chinese Center for Disease Control and Prevention and the investigation work of the staff of the Jingtai County Center for Disease Control and Prevention. Thanks to the contributions of doctors, nurses and other staff in the hospital.